Jess Kendall Leeds CTRU presenting at #ESMOTAT23 on adapting CONCORDE design for the use of durvalumab consolidation in Arm C (now open and recruiting)👏👏CONCORDE Trial Corinne Faivre-Finn 💙 Anthony Chalmers 💙 Prof Sarah R Brown 💙

Investigator meeting at #BTOG2023

Ashley Horne presented our innovative and efficient CONCORDE early phase platform adding DDRis to RT in stage 2-3 NSCLC #BTOG23 Really proud to being involved in this important study Leeds CTRU CONCORDE Trial Alastair Greystoke Cancer Research UK Anthony Chalmers 💙

Blood samples are taken from every CONCORDE patient throughout treatment and follow up for ctDNA analysis (by the excellent CRUK Lung Centre).

We have randomised our first patient to CONCORDE-C. Congratulations to Alastair Greystoke and team at Sir Bobby Robson Cancer Trials Research Centre for your fourteenth randomisation.

Few early phase drug-RT trials have resulted in registration➡️innovative early phase platform trials such as CONCORDE have the potential to change the landscape ▶️multiple drugs tested ▶️bayesian design facilitating rapid dose-escalation ▶️control arm CONCORDE Trial Leeds CTRU

In the #ESTRO23 radiobiology debate Anthony Chalmers 💙 holds up the #CONCORDE trial design as an exemplar of how to discern normal tissue effects from tumour effects when combining DNA damage repair inhibitors with #radiotherapy CONCORDE Trial

We are delighted to be open at 7/17 adult ECMC centres with hopefully more to come soon...

Our CONCORDE statisticians presented to ACTION Leeds to share our expertise with future academic medical and clinical oncologists.

We decided at the safety review committee this week to open up dose level 4 in CONCORDE-A 📈4⃣

We have registered patient 60 today 6⃣0⃣🎉

Good news for the CONCORDE Trial CONCORDE trial: PARPi top of the list for lung cancer radiosensitisers! Thanks Henning Willers, MD and team. #RTdrugcombo Corinne Faivre-Finn 💙 Alastair Greystoke

Alastair Greystoke Tom Newsom-Davis CONCORDE Trial Crispin Hiley Paul Shaw Inclusion of Durva in the #Concorde platform study is indeed an important step forward Leeds CTRU Regarding SOC IO in the sequential CTRT setting the results of PACIFIC5 are eagerly awaited - patients in the conc and seq setting were randomised between consolidation Durva or not

Our first keynote speaker at #CRUKDataConf24 is Corinne Faivre-Finn 💙 from The University of Manchester & The Christie NHS talking about opportunities for high quality real-world evidence (AB)

Our poster on experience pooling control arms within a complex phase I drug-RT platform trial at #ESMOTAT24 Leeds CTRU

We were authorised to escalate to dose level 2 in CONCORDE-C (ceralasertib + RT) yesterday by the oversight committee. ✅🎉📈👏

The CONCORDE early phase platform of DDRi and RT combination highlighed by ⁦⁦Andrea R. Filippi⁩ in the ⁦IASLC⁩ ⁦ESTRO⁩ session ▶️multiarm/multidrugs ▶️efficient Bayesian design ▶️control arm RT alone ⁦⁩ ⁦⁦Leeds CTRU⁩ ⁦Science and Innovation at Cancer Research UK⁩

Receiving the ESTRO Interdisciplinary Anthony Chalmers 💙 delivers a moving and inspiring talk ➡️ give a personal reflection on why #RadOnc research is interdisciplinary Congratulations Anthony 👏👏👏 #ESTRO24

We have just been permitted to dose escalate to dose level 2 in CONCORDE-E ✅